JNJ : Analysis & Opinions

  • Showing 1-100 of 188 items
  • 1
  • 2
  • >>
  1. CR Bard Strong on Acquisitions, FDA Nod for Lutonix DCB - Analyst ...

    December 17, 2014
    CR Bard's initiative to introduce its products in the emerging markets is delivering accretive returns, as the company continues ...
  2. 3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog

    December 17, 2014
    The prospects of the medical devices industry have improved following a Republican victory in the midterm elections.
  3. Will MedTech Gain from Republican Promises? - Industry Outlook

    December 4, 2014
    Will MedTech Gain from Republican Promises? - Industry Outlook
  4. 3 Healthcare Stocks To Profit From An Aging America

    October 29, 2014
    Retirement is supposed to be a relaxing reward for decades of hard work and responsible saving. Unfortunately the reality ...
  5. 3 Healthcare Stocks To Hedge Against Rising Medical Costs

    October 29, 2014
    Retirement is supposed to be a relaxing reward for decades of hard work and responsible saving. Unfortunately the reality ...
  6. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These ...

    August 27, 2014
    Let me start off today's issue with a warning... We're not trying to sound alarmist. It does absolutely zero good ...
  7. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  8. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  9. A Good Start to Q2 Earnings Season - Earnings Trends

    July 16, 2014
    A Good Start to Q2 Earnings Season - Earnings Trends
  10. More Good News to Backstop Market - Ahead of Wall Street

    July 15, 2014
    Stocks today will likely maintain the positive momentum of the last few sessions, and Janet Yellen's Senate testimony comes ...
  11. MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook

    May 1, 2014
    MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
  12. New Brunswick, N.J.-based Johnson & Johnson is probably most famous as the parent company of multiple household products that double as household names.

    How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  13. Earnings Outlook is the Key Factor - Ahead of Wall Street

    April 15, 2014
    My sense is that it will be very hard for the stock market to get its mojo back unless the earnings outlook improves.
  14. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  15. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  16. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  17. Market volatility

    How To Smooth-Out Your Ride In The Stock Market

    March 3, 2014
    Volatility is back. For investors, this nasty problem of gyrating markets can be a real hindrance to your portfolio’s total ...
  18. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  19. Bull of the Day: Valeant Pharma (VRX) - Bull of the Day

    October 13, 2013
    Bull of the Day: Valeant Pharma (VRX) - Bull of the Day
  20. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  21. 14 Companies That Have Raised Their Dividends For 50 Years Or ...

    September 10, 2013
    Imagine if you had bought these stocks 20 years ago.If you had, then right now you'd be earning dividend yields of... ...
  22. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  23. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  24. Medtronic Marking Time

    August 20, 2013
    Medtronic looks stuck in low-growth mode for now, but the shares look undervalued.
  25. Danaher Could Be Loading Up For A Bigger 2014

    August 14, 2013
    Danaher has the resources to make some major purchases, but prices and expectations may be a little high.
  26. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  27. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  28. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  29. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  30. Stryker Seems Back On Track

    July 19, 2013
    Stryker's revenue growth looks fine, but there are still pressures in the end markets.
  31. Where Do The Bears Go Next With St. Jude Medical?

    July 18, 2013
    St. Jude continues to defy bearish expectations of major share loss, but the shares aren't exactly cheap today.
  32. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  33. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  34. Prestige Brands Gets Upgraded: Should You Be Buying?

    July 11, 2013
    At least two investment firms upgraded Prestige Brands' (NYSE:PBH) stock July 9 on news it had acquired a small Australian ...
  35. Intuitive Surgical's Miss Looks Systemic And Company-Specific

    July 9, 2013
    A surprising drop in U.S. system placements is going to put Intuitive Surgical in the penalty box.
  36. Profiting With Straddles This Earnings Season - Know Your Options

    July 2, 2013
    Profiting With Straddles This Earnings Season - Know Your Options
  37. CHMP Positive on Dendreon's Provenge - Analyst Blog

    July 1, 2013
    The CHMP provided a positive opinion on Dendreon's marketing application for Provenge.
  38. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  39. Data from Bayer/JNJ's Xarelto Study - Analyst Blog

    June 25, 2013
    Bayer's announced that it will present data from a Xarelto clinical program.
  40. Rising 10-Year Yields Could Crush Popular Dividend ETFs

    June 21, 2013
    Seduced by backward-looking dividend increase streaks, investors have fallen in love with dividend ETFs such as the Vanguard ...
  41. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  42. Little Left To Dendreon But The Hope Trade

    May 10, 2013
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  43. Recent Financials May Not Be Entirely Fair To Hologic

    May 8, 2013
    Macro pressures are outweighing solid internal progress at Hologic.
  44. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  45. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  46. Kimberly-Clark Looks Way Too Expensive For What It Is

    April 22, 2013
    Kimberly-Clark's growth prospects make today's valuation hard to justify.
  47. Is Controversy About Robot-Assisted Surgery Showing In Intuitive ...

    April 19, 2013
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  48. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  49. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  50. Pipeline Setback for Idenix - Analyst Blog

    February 7, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical development ...
  51. P&G Rewards Longs With Better Sales And Stronger Margins

    January 30, 2013
    Procter & Gamble is delivering on its promises for better performances.
  52. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  53. Shabby Reporting And Questionable Prospects At Abbott Labs

    January 28, 2013
    Poor reporting and weak margins undermine the potential of Abbott.
  54. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  55. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  56. Back to Neutral on Bayer - Analyst Blog

    December 26, 2012
    We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous ...
  57. Gilead Plans to Split Stock 2-for-1 - Analyst Blog

    December 11, 2012
    Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, which will ...
  58. Hard Times Continue For Align - Analyst Blog

    December 7, 2012
    Investors were left disappointed when Align Technologies (ALGN), a major player in the malocclusion market, announced that ...
  59. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  60. Medtronic's Growth Looks Good, But Can It Last?

    November 22, 2012
    Medtronic may not be a super grower anymore, but it's doing better than the Street seems to acknowledge
  61. Schiff Creates A Bidding War

    November 19, 2012
    Two weeks after Bayer offered to buy Schiff for $34 a share, Reckitt Benckiser is offering $42 a share. A bidding war has ...
  62. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  63. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  64. GE's Results Reflect An Industrial Slowdown, But Valuation Isn't ...

    October 23, 2012
    GE may have disappointed, but the company and its stock are both in good shape today.
  65. These Companies Have Raised Their Dividends for 50 Consecutive ...

    October 18, 2012
    Imagine if you had bought these stocks 20 years ago. If you had, then right now you'd be earning dividend yields of... 27%... ...
  66. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  67. The Long-Tail Value Of Supreme Brands

    September 25, 2012
    Brand value can make old products into incredible winners.
  68. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  69. Slew of Product Recalls at Covidien - Analyst Blog

    August 24, 2012
    Recently, health care products major Covidien plc. (COV) has been hit by a number of product recalls, the most significant ...
  70. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  71. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  72. Stryker Remains Neutral - Analyst Blog

    August 8, 2012
    We reaffirm our Neutral recommendation on Stryker Corp. (SYK). Stryker reported second quarter 2012 adjusted earnings of ...
  73. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  74. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  75. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  76. Setback for Chelsea Therapeutics - Analyst Blog

    July 6, 2012
    Chelsea Therapeutics International, Ltd. (CHTP) recently suffered a setback when the US Food and Drug Administration (FDA), ...
  77. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  78. Integra's New PIP Fixation Device - Analyst Blog

    June 22, 2012
    Medical products company, Integra LifeSciences Holdings Corporation (IART) unveiled its latest device for fixing proximal ...
  79. 3M Set to Acquire FSTech - Analyst Blog

    June 22, 2012
    3M Company (MMM) is all set to acquire business of Federal Signal Technologies Group (FSTech), a provider of electronic toll ...
  80. Covidien Promotes Zogenix's Product - Analyst Blog

    June 8, 2012
    The pharmaceutical unit of Covidien plc (COV) and Zogenix Inc. (ZGNX) have recently agreed to co-endorse a prescription medicine ...
  81. Rockwood Has Its Risks, But Also Some Apparent Value

    May 31, 2012
    Rockwood has economic risks, but offers real growth opporunities in higher-value lithium and ceramics.
  82. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America to your ...
  83. Beware These Dividend Red Flags

    April 17, 2012
    Companies paying out more than half their earnings or offering very rich yields might be riskier then investors reckon, says ...
  84. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  85. Ruling Or Not, Healthcare Still Wins

    March 29, 2012
    The Affordable Care Act finally goes in front of the Supreme Court. However, the Justice’s ruling may not matter. Healthcare ...
  86. Dividends That Will Keep Growing

    March 26, 2012
    The value that these companies have created over the years is mainly due to the dividends they pay out to investors.
  87. 5 Reasons to Love Dividend Growth

    March 15, 2012
    What a smart strategy for DIY investors: It’s idiot and inflation proof, it’s money for nothing…and best of all, it works, ...
  88. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  89. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  90. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  91. Procter & Gamble Feels The Pinch

    January 31, 2012
    U.S sales growth combined with rising input costs helped put a lid on the company's quarter.
  92. Colgate-Palmolive Has Growth, But It'll Cost Ya

    January 30, 2012
    Colgate has great growth, but a valuation to match.
  93. Treat Stocks Like Savings

    January 30, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  94. Stryker Leaning Away From Knees

    January 26, 2012
    A fair amount of future growth is already baked into Stryker’s valuation.
  95. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  96. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  97. A Better ETF for Metals Investors

    January 11, 2012
    The most common silver and gold ETFs may present risks unknown to most investors, says asset manager and analyst Mo Dawoud. ...
  98. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  99. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year. ...
  100. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  • Showing 1-100 of 188 items
  • 1
  • 2
  • >>
Trading Center